Jenburkt Pharmaceuticals Ltd — Updates, 09-07-2025: Company Update

Jenburkt Pharmaceuticals has confirmed compliance with share dematerialization processes for the quarter ended June 30, 2025. Its registrar and transfer agent, Bigshare Services, verified that securities received for demat were processed—either accepted or rejected—and corresponding certificates were cancelled and replaced with electronic records within 15 days. This ensures smooth securities handling and accurate shareholder records, supporting seamless trading and ownership transparency for investors.